Douglas B. Given - 05 May 2023 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Role
Director
Signature
/s/Douglass Given
Issuer symbol
ARWR
Transactions as of
05 May 2023
Transactions value $
-$265,850
Form type
4
Filing time
08 May 2023, 18:29:07
Previous filing
01 Mar 2023
Next filing
19 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARWR Common Stock Sale -$266K -6.5K -5.24% $40.90 118K 05 May 2023 Direct F1, F2
holding ARWR Common Stock 13K 05 May 2023 By Trust F3
holding ARWR Common Stock 12.5K 05 May 2023 By Trust F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $40.59 to $41.22, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F2 Includes previously reported shares of common stock underlying Restricted Stock Units granted to the reporting person which are subject to certain vesting conditions.
F3 Represents securities owned directly by Anne Given Trust ("AG Trust"). Douglas Given, as co-trustee of AG Trust, may be deemed to beneficially own the securities owned directly by AG Trust.
F4 Represents securities owned directly by Katherine Given Ligtenberg Trust ("KGL Trust"). Douglas Given, as co-trustee of KGL Trust, may be deemed to beneficially own the securities owned directly by KGL Trust.